Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Northcoast Research Downgrades Franklin Electric to Neutral

Northcoast Research analyst Ryan Connors downgrades Franklin Electric (NASDAQ:FELE) from Buy to Neutral.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Northcoast Research analyst Ryan Connors downgrades Franklin Electric (NASDAQ:FELE) from Buy to Neutral.

Mizuho Maintains Neutral on Ansys, Lowers Price Target to $285

By Benzinga Newsdesk

Today, 11:56 PM

Mizuho analyst Matthew Broome maintains Ansys (NASDAQ:ANSS) with a Neutral and lowers the price target from $310 to $285.

ANSS

News

UPDATE: Pfizer Says Change Of Delivery Schedule Does Not Impact FY22 Commitment Of Doses To Be Delivered To European Commission Member States In 2022

By Michael Horton

Today, 11:56 PM

-Reuters

BNTX

Fed’s Powell Says But War Remains A Significant Risk; It Is A Source Of Risk To Both U.S. And Global Economy

By Happy Mohamed

Today, 11:56 PM

- Reuters

SPY

FDA
News

Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy For Treatment Of B-Cell Non-Hodgekin Lymphomas

By Benzinga Newsdesk

Today, 11:56 PM

Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic

MBIO

Northcoast Research Downgrades Franklin Electric to Neutral

Related Posts

Mizuho Maintains Neutral on Ansys, Lowers Price Target to $285

UPDATE: Pfizer Says Change Of Delivery Schedule Does Not Impact FY22 Commitment Of Doses To Be Delivered To European Commission Member States In 2022

Fed’s Powell Says But War Remains A Significant Risk; It Is A Source Of Risk To Both U.S. And Global Economy

Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy For Treatment Of B-Cell Non-Hodgekin Lymphomas